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OBJECTIVE: We describe an IncX4 pHC891/16mcr plasmid carrying mcr-1 in a colistin-resistant and carbapenem-
susceptible E. coli isolate (HC891/16), ST156, which caused a blood infection in a Brazilian patient with
gallbladder adenocarcinoma.
METHODS: Strain HC891/16 was subjected to whole genome sequencing using the MiSeq Platform (Illumina,
Inc., USA). Assembly was performed using Mira and ABACAS.
RESULTS: The isolates showed resistance only to ciprofloxacin, ampicillin and cefoxitin, and whole-genome
sequencing revealed the presence of aac(6’)Ib-cr and blaTEM1.
CONCLUSION: Our findings warn of the possible silent dissemination of colistin resistance by carbapenem-
susceptible mcr-1 producers, as colistin susceptibility is commonly tested only among carbapenem-resistant
isolates.
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Liu et al. (1) reported the emergence of an mcr-1 plasmidial
resistance mechanism to colistin in E. coli from China, which
was followed by many reports worldwide (2-7). In Brazil,
Fernandes et al. (8) reported an IncX4 plasmid carrying mcr-1
in E. coli isolated from a soft tissue infection in a human.
These authors also described evidence that E. coli harbor-
ing mcr-1 has been occurring in food-producing animals in
Brazil since at least 2012 (9). However, to date, there is no
consensus in the scientific community regarding the clinical
importance of this new colistin resistance mechanism, as it
confers a low level of colistin resistance compared with
chromosomal mechanisms and appears to have been pre-
sent for a long time (10). Epidemiological data can be used
to elucidate the impact of this plasmidial mechanism for
the dissemination of colistin resistance. In this study, we
describe a plasmid-mediated mcr-1 in a colistin-resistant and
carbapenem-susceptible E. coli isolate that caused a blood
infection in a cancer patient from Brazil.
ECF, a 75-year-old female with a gallbladder adenocarci-
noma diagnosed in January 2016, was admitted to Hosp-
ital das Clínicas, São Paulo for investigation, and a hepatic
drain was placed. Bile cultures were positive for Enterococcus
faecalis susceptible to all drugs. One month later, she devel-
oped fever and presented to the emergency room (ER). Blood
cultures were positive for E. coli phenotypically classified as
an ESbL-producer that was susceptible to carbapenem and
aminoglycosides, resistant to ciprofloxacin (MIC44 mg/L)
and with a colistin MICp0.5 mg/L. She received mer-
openem with good clinical evolution. One month later, she
began ambulatory chemotherapy (cisplatin and gemcita-
bine). On April 11, 2016, she returned to the ER with a high
fever, leukocytosis, and elevated CRP, and her bloodcultures
were positive for E. coli with a different phenotypic profile.
It was susceptible to amikacin (MIC, p2 mg/L), gentamicin
(MIC, 2 mg/mL), cefuroxime (MIC, 4 mg/L), ceftazidime
(MIC, p1 mg/L), ceftriaxone (MIC, p1 mg/L), cefepime
(MIC, p1 mg/L), ertapenem (MIC, p0.5 mg/L), imipenem
(MIC, p0.25 mg/L), meropenem (MIC, p0.25 mg/L),
piperacillin/tazobactam (MIC, p4 mg/L) and tigecycline
(MIC,p0.5 mg/L); intermediate to cefoxitin (MIC, 16 mg/L);DOI: 10.6061/clinics/2017(10)09
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and resistant to ampicillin (MIC, 432 mg/L) and ciproflox-
acin (MIC, 44 mg/L). The colistin MIC was 4 mg/L. This
strain was positive for mcr-1 by PCR using specific primers
as previously described (1) and was denominated HC891/16.
The patient received antibiotics and support medication
and was discharged with no infection. The identification
and antimicrobial susceptibility tests of the isolates were
performed by Vitek-MS and Vitek-2 (bioMeriéux, France),
respectively, and colistin susceptibility was confirmed by
CLSI broth microdilution (11). Strain HC891/16 was sub-
jected to whole genome sequencing using the MiSeq Plat-
form (Illumina, Inc., USA). The sequencing library was
prepared from 40 ng of HC891/16 strain total DNA using the
Illumina Nextera DNA library preparation kit (Illumina, Inc.,
USA). After quantification of the resulting library using the
KAPA Library Quantification Kit, a sequencing run was
performed in the Illumina MiSeq to generate 250 bp paired-
end reads. Assembly was performed using Mira (12) and
ABACAS (13), resulting in 71 contigs encompassing the main
chromosome (5,053,377 bp) and at least one plasmid (33,227 bp).
Genome sequences were deposited in GenBank under acces-
sion number MRDN01000000. The presence of resistance
genes was determined with ResFinder (14).
The strain HC891/16 belongs to sequence type (ST) 156. E.
coli ST156 harboring the mcr-1 gene was previously detected
in one duck sample, from China, showing a carbapenem-
resistant profile (15). The mcr-1 gene is in pHC891/16mcr,
a 33.2-kb plasmid, which is classified as incompatibility
group IncX4. This plasmid shows 100% nucleotide identity
to pICBEC7Pmcr (CP017246.1), and it is found in animal
samples from Latin America. Furthermore, 99% nucleotide
identity was observed when this plasmid was compared
with the following previously described conjugative plas-
mids harboring the mcr-1 gene: pOW3E1 (KX129783.1),
detected in environmental and animal samples; pMCR1.2-
IT (KX236309.1), harboring a mcr-1.2 variant of K. pneumoniae
from a human infection in Italy; pmcr1_IncX4 (KU761327.1),
found in clinical isolates from China; pMCR1-NJ-IncX4
(KX447768.1), found in a carbapenem-resistant E. coli iso-
late harboring mcr-1 and blaNDM-5, causing a complicated
urinary tract infection in the USA (16-19). The IncX4 plas-
mid appears to be globally disseminated among environ-
mental, food and human mcr-1 producer strains, including
KPC-2 and a mcr-1 producer-K. pneumoniae strain that have
been recently reported in Brazil (20). In addition to mcr-1,
we also detected the presence of genes aac(6')Ib-cr and
blaTEM1 in the HC891/16 strain.
In a previous study from our institution, carbapenem
susceptibility was observed in 21.5% of all colistin-resistant
Gram-negative isolates examined in the last five years (21).
It is important to highlight that the carbapenem-susceptible
andmcr-1-positive phenotype may easily go unnoticed because
many clinical laboratories in Brazil only test or release
colistin susceptibility to clinicians when the isolates are
carbapenem-resistant. Olaitan et al. (22) state that clinicians
and microbiologists should be vigilant for the possible
existence of colistin-resistant bacteria not only in patients
undergoing colistin therapy but also in patients who are
not receiving the drug, as resistant bacteria could later
be selected if colistin is used. In Brazil, colistin has been
used as a first-line drug in many critical care units due
to high rates of carbapenem-resistance among the OXA-
23-producer Acinetobacter baumannii and KPC- producer
K. pneumoniae (23,24).
The dissemination of colistin resistance is a serious prob-
lem for infection control, as this antimicrobial is one of the
last therapeutic options for infections caused by multidrug-
resistant Gram-negative isolates. At this time, attention should
be paid to this carbapenem-susceptible-mcr-1 phenotype,
as these isolates may be silently contributing to the spread
of colistin resistance.
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